ELACIN

This brand name is authorized in Nigeria.

Active ingredients

The drug ELACIN contains one active pharmaceutical ingredient (API):

1	Febuxostat UNII 101V0R1N2E - FEBUXOSTAT
	Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.
	Read more about Febuxostat

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-1652	Tablet	Elacin 40 Tablet TAB 40 mg 3 x 10's (in Alu-Alu blisters)	Film-coated tablet. White coloured, round shaped, biconvex, film-coated tablets	29/03/2021
C4-1653	Tablet	Elacin 80 Tablet TAB 80 mg 3 x 10's (in Alu-Alu blisters)	Film-coated tablet. White coloured, round shaped, biconvex, film-coated tablets	29/03/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M04AA03	Febuxostat	M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production
Discover more medicines within M04AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-1652, C4-1653